Advanced Biomarker Strategies in Oncology Drug Development
This invitation only think tank brings together the leaders in clinical R&D, oncology, drug development, and translational research in an exciting and engaging environment to deliver and develop solutions, industry standards and practical applications for biomarker development and validation.
With the help of industry leaders from Bristol-Myers Squibb, Eli Lilly, Genzyme, GSK, MedImmune, Merck, Novartis, OncoMed, and Roche, we’ve hand-selected the premiere scientists and clinical research professionals to convene, share, and move forward the science and become a catalyst for progress.
- Integrated strategies to facilitate early decision making for therapeutic viability, target patient populations, and costly pivotal trials.
- Insights into utilizing models for preclinical evaluation to identify pharmacodynamic and predictive biomarkers.
- Best practices for the growing trend in developing novel combination approaches and companion diagnostic co-development in oncology clinical trials.
- Clarify requirements for translational research in the clinical setting and how to bridge the gap with maximum effectiveness.
Distinguished Speaking Faculty and Scientific Advisors including:
|Jeffrey S. Humphrey, M.D.
Vice President, Oncology Medical Strategy, U.S. Pharmaceuticals Medical Affairs
|Samuel C. Blackman M.D.
Associate Director, Experimental Medicine
|Ann Kapoun, PhD
Director, Translational Medicine
|John Brandt, MD
Oncology Biomarker Sciences Group